昊海生科(688366.SH):2024年度淨利潤4.2億元,同比增長0.97%
格隆匯2月19日丨昊海生科(688366.SH)公佈2024年度業績快報,報告期內,公司實現營業收入26.98億元,同比增長1.64%;實現歸屬於母公司股東的淨利潤4.2億元,同比增長0.97%;實現歸屬於母公司股東的扣除非經常性損益的淨利潤3.81億元,同比減少0.57%;報告期內,公司堅持聚焦主營業務發展戰略,持續深耕現有產品市場,通過優化產品結構和提升運營效率,增強盈利能力。同時,公司加大研發投入力度,積極推進技術創新和產品升級,推動業務規模穩健增長,整體經營業績穩中有升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.